| abstract |
This invention relates, in part, to methods and compositions for determining altered susceptibility of a human immunodeficiency virus ('HIV') to the non-nucleoside reverse transcriptase inhibitors ('NNRTIs') efavirenz ('EFV'), nevirapine ('NVP'), and delavirdine ('DLV'), the nucleoside reverse transcriptase inhibitor AZT, and the integrase strand transfer inhibitors diketo acid 1, diketo acid 2, and L-870,810 by detecting the presence of a mutation or combinations of mutations in the gene encoding HIV reverse transcriptase that are associated with altered susceptibility to the anti-HIV drugs. |